review hit cycl biotech
vertex report sales/earn provid guidanc updat
investor compani plan beyond compani handili
beat sales/earn expect see also report strong
trikafta sale number includ inventori build
homozyg patient would
previous approv cf therapi kalydeco orkambi symdeko
guidanc also stronger expect consensu
potenti benefit trikafta us uptak surg ex-u patient add due
recent agreement variou countri given early/mid-stag pipelin
gather momentum consider potenti materi catalyst
asid strong trikafta launch believ revenu
posit impact rapid ex-u uptak due reimburs approv
orkambi/symkevi franc england spain etc patient
cover potenti price leverag switch trikafta
kalydeco/orkambi/symdeko triplet price greater
back trikafta earli commerci uptak expect momentum
continu submiss snda triplet younger
patient age potenti eu approv previous written
impact strong triplet launch could make room addit upsid
revis sales/earn street estim medium-term
oper margin improv top-lin expans anticip
substanti re-invest pipelin long-term guidanc
growth opex san francisco manag highlight belief
clinic program would import sustain growth cf busi
suggest heathi appetit bd in-licens
emerg one potenti growth pillar
phase proof-of-concept studi continu enrol patient earli day
intrigu kol call potenti address diseas manifest
lung liver await initi result measur function serum
level expect
updat model follow rais estim reflect
guidanc earli inning beat-and-rais cycl could
edg closer prior thought could worth
believ high multipl place continu support sales/
earn upgrad pipelin updat next quarter
year price histori
global biotechnolog
compani discov develop
seriou diseas
analyst certif import disclosur see disclosur
orkambi achiev patient penetr homozyg
symdeko tez/iva success approv
get homozyg penetr
trikafta launch updat trikafta us price similar kalydeco
provid visibl pipelin beyond cf
rate vertex outperform price target
compani posit deliv strong sale earn
growth next five year potenti even
greater growth near- tezacaftor/ivacaftor mid-term triplet
therapi homozyg cf patient
product launch outperform opex growth remain steadi
addit catalyst aatd phase readout pain
beta-thalassemia etc also posit compani well
could begin upsid stori believ
updat phase studi trikafta
eu approv submiss younger age patient us
data phase dose-rang studi potenti once-
daili regimen phase studi
kidney diseas initi pipelin updat
orkambi/symdeko reimburs approv addit ex-
us countri updat phase studi pain
vertex secur broad reimburs cf franchis ex-u
rapidli expect
symdeko sale continu ramp faster expect
triplet trikafta approv earlier expect upsid
number price higher expect
disclos addit pipelin opportun
failur secur cf regulatori approv and/or reimburs
lower expect uptak orkambi/symdeko
compet regimen other abbvie/proteostasi
approv earlier expect take signific market share
pt vs previous util composit valuat methodolog biotech compani util
forward price-to-earnings multipl npv adj estim earn sinc biotech high-growth/high-expect sector aim rank
target compani base qualiti sale and/or earn growth vs peer group peer index nbi expect
earn growth next three five year well expect higher termin multipl
due perceiv greater certainti qualiti sales/earn growth appli discount rate vs peer group
average
slow cf sale disappoint commerci launch penetr tezacaftor/ivacaftor pipelin failur triplet regimen and/
regulatori non-approv kalydeco label extens
varianceproduct revenu revenu collabor product develop gener administr asset impair cost expens loss oper incom expens incom expens loss provis benefit incom tax benefit incom non-cash incom loss incom loss attribut vertex outstand vertex pharmaceut
statement revenu royalti revenu collabor total product royalti research develop sale gener administr restructur expenses- intang asset impair charges- total cost expens incom loss oper interest incom net- interest expens incom expens incom loss provis benefit incom tax provis benefit incom provis non-cash taxes- net incom loss net incom loss attribut vertex dilut share outstand sale oper outperform
revenu compound-annual-growth-rate net profit/loss y/i growth share count compound-annual-growth-rate us adj ep compound-annual-growth-rate group index nbi indexp group adj ep compound-annual-growth-rate expect nbi index ep ltg cagrpeer group termin multipl price-to-earnings peer group beg us termin multipl peer group multipl compound-annual-growth-rate peer grouptermin valu us wacc peer group larg cap biotech averag us discount rate adj ep price-to-earnings valuat compound-annual-growth-rate y/i growth share count compound-annual-growth-rate expect nbi index ep ltg cagraverag price-to-earnings peer group beg peer group multipl compound-annual-growth-rate peer groupbloomberg peer group larg cap biotech averag
